Although PSC27-BLEO CM enhanced viability of PC3 exposed to MIT at 0.1–1.0 μM, a range of dose approaching its serum concentrations in clinical settings [39, 40], EREG-neutralization markedly offset cancer resistance in a similar way as EREG mAb was combined with cetuximab (Fig. 4h). The gene discussed is EREG; the disease is cancer.